185 related articles for article (PubMed ID: 18838744)
1. Emerging resistance profiles of newly approved antiretroviral drugs.
Daar ES
Top HIV Med; 2008; 16(4):110-6. PubMed ID: 18838744
[TBL] [Abstract][Full Text] [Related]
2. Incorporating novel virologic tests into clinical practice.
Daar ES
Top HIV Med; 2007; 15(4):126-9. PubMed ID: 17720997
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure.
Llibre JM; Schapiro JM; Clotet B
Clin Infect Dis; 2010 Mar; 50(6):872-81. PubMed ID: 20158400
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral therapy: new drugs, formulations, ideas, and strategies.
Eron JJ
Top HIV Med; 2009 Dec; 17(5):146-50. PubMed ID: 20068261
[TBL] [Abstract][Full Text] [Related]
5. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
6. Effect of antiretroviral resistance on response in treatment-experienced patients.
Kuritzkes DR
AIDS Read; 2003 Dec; 13(12 Suppl Antiretroviral):S5-11. PubMed ID: 19967805
[TBL] [Abstract][Full Text] [Related]
7. First-line regimen failure of antiretroviral therapy: a clinical and evidence-based approach.
Bogoch I; Walmsley S
Curr Opin HIV AIDS; 2009 Nov; 4(6):493-8. PubMed ID: 20048716
[TBL] [Abstract][Full Text] [Related]
8. New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.
Hughes CA; Robinson L; Tseng A; MacArthur RD
Expert Opin Pharmacother; 2009 Oct; 10(15):2445-66. PubMed ID: 19678794
[TBL] [Abstract][Full Text] [Related]
9. Raltegravir: the first HIV integrase inhibitor.
Cocohoba J; Dong BJ
Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
[TBL] [Abstract][Full Text] [Related]
10. New developments in HIV drug resistance.
Cane PA
J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i37-40. PubMed ID: 19675018
[TBL] [Abstract][Full Text] [Related]
11. Nucleoside analogue reverse transcriptase inhibitor options: a re-examination of the class.
Hammer SM
Top HIV Med; 2006; 14(4):140-3. PubMed ID: 17114828
[TBL] [Abstract][Full Text] [Related]
12. Treatment of heavily antiretroviral-experienced HIV-infected patients.
Lunzen Jv
AIDS Rev; 2007; 9(4):246-53. PubMed ID: 18219368
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral treatment of HIV infection: Swedish recommendations 2007.
Josephson F; Albert J; Flamholc L; Gisslén M; Karlström O; Lindgren SR; Navér L; Sandström E; Svedhem-Johansson V; Svennerholm B; Sönnerborg A
Scand J Infect Dis; 2007; 39(6-7):486-507. PubMed ID: 17577810
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and drug-drug interactions of antiretrovirals: an update.
Dickinson L; Khoo S; Back D
Antiviral Res; 2010 Jan; 85(1):176-89. PubMed ID: 19665485
[TBL] [Abstract][Full Text] [Related]
15. Resistance to novel drug classes.
Marcelin AG; Ceccherini-Silberstein F; Perno CF; Calvez V
Curr Opin HIV AIDS; 2009 Nov; 4(6):531-7. PubMed ID: 20048722
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic characteristics of investigational and recently approved agents for the treatment of HIV.
Kiser JJ
Curr Opin HIV AIDS; 2008 May; 3(3):330-41. PubMed ID: 19372987
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis and treatment of lipodystrophy: what clinicians need to know.
Sattler FR
Top HIV Med; 2008; 16(4):127-33. PubMed ID: 18838747
[TBL] [Abstract][Full Text] [Related]
18. HIV/AIDS pathogenesis and treatment options focusing on the viral entry inhibitors.
Jones R; Gazzard B
Expert Rev Anti Infect Ther; 2006 Apr; 4(2):303-12. PubMed ID: 16597210
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from Central West Brazil.
Cardoso LP; Queiroz BB; Stefani MM
J Clin Virol; 2009 Oct; 46(2):134-9. PubMed ID: 19682948
[TBL] [Abstract][Full Text] [Related]
20. HIV resistance: frequency, testing, mechanisms.
Kuritzkes DR
Top HIV Med; 2007; 15(5):150-4. PubMed ID: 18073450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
